Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,138,305 papers from all fields of science
Search
Sign In
Create Free Account
cyclazosin
Known as:
(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)octahydroquinoxalin-1-yl)furan-2-ylmethanone hydrochloride
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (3)
Adrenergic alpha-2 Receptor Antagonists
Quinazolines
Quinoxalines
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Role of α 1 -adrenergic receptor subtypes in contractility of the rabbit abdominal aorta in vitro
J. Gnus
,
A. Czerski
,
+7 authors
A. Chrószcz
2013
Corpus ID: 53050158
Investigation of the effect of α 1 -adrenergic receptor subtypes on the contraction of the abdominal aorta will allow for more…
Expand
2008
2008
Role of α1‐adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse
S. Bexis
,
J. Docherty
British Journal of Pharmacology
2008
Corpus ID: 25331508
We have investigated the ability of α1‐adrenoceptor antagonists to affect the hyperthermia produced by methylenedioxy…
Expand
2003
2003
Searching for cyclazosin analogues as alpha(1B)-adrenoceptor antagonists.
D. Giardiná
,
O. Polimanti
,
+6 authors
A. Leonardi
Il Farmaco
2003
Corpus ID: 22564254
A series of quinazoline derivatives, 2-20, structurally related to the racemic alpha(1)-adrenoceptor antagonist cyclazosin (1…
Expand
1995
1995
Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist.
D. Giardiná
,
M. Crucianelli
,
C. Melchiorre
,
C. Taddei
,
R. Testa
European Journal of Pharmacology
1995
Corpus ID: 38855666
The binding profile of cyclazosin, a new prazosin-related alpha 1-adrenoceptor antagonist, at alpha 1-, alpha 2-adrenoceptors…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE